Compounds and methods for inhibiting hepatitis C virus replication
US7465537B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 1, 2005 |
| Grant date | Dec 16, 2008 |
| Priority date | — |
| Expiry date | Dec 12, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16B15/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The inventors have discovered that an ATPase-deficient dominant-negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal structure of a multi-enzyme NS3 complex on a DNA substrate is also provided. The inventors have tested a peptide matching the sequence of a portion of NS3 that interacts with another NS3 molecule for inhibiting HCV replication. The peptide inhibits HCV replication. Accordingly, the invention provides a method of inhibiting HCV replication in cells infected with HCV involving transforming the cells with a vector expressing a dominant-negative mutant NS3 gene. The invention also provides a method of inhibiting HCV replication in cells infected with HCV involving administering to the cells a dominant-negative mutant NS3 protein. The invention also provides peptides and agents that inhibit HCV replication and methods of identifying agents that inhibit HCV replication.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.